DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
Vilzemetkib
CAS 1363402-44-1
MF C36H36F2N4O5 MW 642.7 g/mol
1-N‘-[4-[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6-methoxyquinolin-4-yl]oxy-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- 1,1-Cyclopropanedicarboxamide, N-[4-[[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6-methoxy-4-quinolinyl]oxy]-3-fluorophenyl]-N’-(4-fluorophenyl)-
- 1-N’-[4-[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6-methoxyquinolin-4-yl]oxy-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- 1363402-44-1
- N-[4-[[7-[[1-(Cyclopentylamino)cyclopropyl]methoxy]-6-methoxy-4-quinolinyl]oxy]-3-fluorophenyl]-N’-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
hepatocyte growth factor receptor inhibitor, antineoplastic, AL 2846, FJ4Y6XP24Y
Vilzemetkib (also known as AL2846) is an investigational, orally active small-molecule drug that acts as a potent inhibitor of the c-Met receptor tyrosine kinase, a protein often overexpressed in cancers, aiming to block tumor growth, survival, and spread by disrupting key cellular signals. It’s being studied in clinical trials, often in combination with other agents like TQB2450 (a PD-L1 inhibitor), for advanced cancers such as esophageal and liver cancer, showing promise in immunotherapy-resistant patients.
How it Works:
- Targets c-Met: Vilzemetkib binds to the c-Met protein, preventing its phosphorylation (activation).
- Blocks Signaling: This action disrupts downstream pathways crucial for cancer cell proliferation, survival, invasion, metastasis, and new blood vessel formation (angiogenesis).
Development & Use:
- Developer: Developed by Advenchen Laboratories.
- Status: Investigational drug, currently in clinical trials.
- Research Focus: Studied for cancers like esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC).
Key Information:
- Chemical Name: 1,1-Cyclopropanedicarboxamide, N-[4-[[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6-methoxy-4-quinolinyl]oxy]-3-fluorophenyl]-N′-(4-fluorophenyl)-.
- Purpose: Potential anti-cancer (antineoplastic) activity.
- OriginatorAdvenchen Laboratories
- DeveloperAdvenchen Laboratories; Chia Tai Tianqing Pharmaceutical Group
- ClassAntineoplastics; Small molecules
- Mechanism of ActionReceptor protein-tyrosine kinase antagonists
- Phase IIINon-small cell lung cancer; Thyroid cancer
- Phase IILung cancer; Ovarian cancer
- Phase I/IIColorectal cancer; Neurofibromatosis 1; Pancreatic cancer
- No development reportedSolid tumours
- 28 Oct 2025No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (PO, Capsule)
- 10 Oct 2025700363489: CTP push: KDM and HE updated
- 26 Aug 2025Chemical structure information added.
Vilzemetkib is an orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration vilzemetkib targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US73570351&_cid=P20-MJ6JF6-22611-1
EXAMPLE 6
N-(4-(7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-3-fluoro-phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
| The title compound was prepared by similar manner to Example 3, by using cyclopentanone instead of tetrahydro-4H-pyran-4-one. Mass: (M+1), 643 |
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022268158&_cid=P20-MJ6JJ7-25153-1
WO2012034055 discloses N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolone-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (hereinafter referred to as compound (I)) as a c-Met kinase inhibitor and its use in inhibiting tyrosine kinase activity. Compound (I) is a novel class of compounds with excellent pharmacological properties, capable of inhibiting the activity of various protein tyrosine kinases, such as c-Met, VEGFr, EGFr, c-kit, PDGF, FGF, SRC, Ron, Tie2, etc. This disclosure relates to the treatment of neurofibromatosis type I with compound (I).
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012034055&_cid=P20-MJ6JLU-26634-1
Example 6
N-(4-(7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-3-fluoro-phenyl)-N-(4-fluorophenyl)cyclopropane- 1,1-dicarboxamide
The title compound was prepared by similar manner to Example 3, by using cyclopentanone instead of tetrahydro-4H-pyran-4-one. Mass: (M + 1), 643
PAT
- Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereofPublication Number: EP-4279138-A2Priority Date: 2018-03-02
- Compounds As c-Met Kinase InhibitorsPublication Number: US-2012123126-A1Priority Date: 2010-09-12
- Compounds as c-Met kinase inhibitorsPublication Number: US-8664244-B2Priority Date: 2010-09-12Grant Date: 2014-03-04
- Compounds as c-met kinase inhibitorsPublication Number: WO-2012034055-A2Priority Date: 2010-09-12
- Use of compound as c-met kinase inhibitor for treatment of neurofibromatosis type iPublication Number: WO-2022268158-A1Priority Date: 2021-06-23
- Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibodyPublication Number: US-2023263795-A1Priority Date: 2020-06-02
- Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereofPublication Number: EP-3766870-A1Priority Date: 2018-03-02
- Crystalline of compound as c-met kinase inhibitor and preparation method therefor and use thereofPublication Number: US-2021047272-A1Priority Date: 2018-03-02
- Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereofPublication Number: US-11279676-B2Priority Date: 2018-03-02Grant Date: 2022-03-22
AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
////////Vilzemetkib, hepatocyte growth factor receptor inhibitor, antineoplastic, AL 2846, FJ4Y6XP24Y
New Drug Approvals 